search
Back to results

Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

Primary Purpose

Cardiac Disease

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Edoxaban
Standard of Care (SOC)
Sponsored by
Daiichi Sankyo, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cardiac Disease focused on measuring Children, Pediatrics, Cardiac disease with potential for thromboembolic complications, Prophylactic treatment, Anticoagulant drugs

Eligibility Criteria

1 Day - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Is a child with cardiac disease who is at risk for thromboembolic complications and requires at least 3 months antithrombotic anticoagulant prophylaxis

Either one of the following:

  1. a child with cardiac disease who has a history of cardiac shunt occlusion/thrombosis, with shunt still in place (secondary prevention).

    OR

  2. a child with cardiac disease who requires (including those already taking, and those not yet taking) anticoagulation for primary prevention of TE.

Cardiac conditions known to significantly increase the risk of thrombosis (hence, indications for primary TE prevention) are defined in Antithrombotic Therapy and Prevention of Thrombosis. Some examples of cardiac conditions at risk of thrombosis are Fontan surgery, heart failure, Kawasaki disease, and Blalock-Taussig and Glenn surgery.

  • Is a male or female child between 1 and <18 years of age (children between 38 weeks gestational age and 1 year of age will be included in the study, however, only after the safety and efficacy data of 50 subjects between 1 and <18 years of age in the edoxaban arm have been evaluated at the end of the 3-month treatment period)
  • Has parent(s)/legal guardian(s) or legally acceptable representative who is informed and provides signed consent for the child, to participate in the study with edoxaban treatment. Pediatric participants with appropriate intellectual maturity will be required to sign an assent form in addition to the signed informed consent from the parent(s)/legal guardian(s) or any legally acceptable representative.
  • If a female subject of childbearing potential, tests negative for pregnancy at Screening and consents to avoid becoming pregnant by using a locally approved contraception method throughout the study

Exclusion Criteria:

  • Has evidence of symptomatic venous or arterial thrombosis and/or asymptomatic intracardiac thrombosis confirmed by a transthoracic echocardiogram during study screening period
  • Has mechanical heart valve(s)
  • Has active bleeding or high risk of bleeding contraindicating treatment with anticoagulant
  • Takes antithrombotic therapy (other than low-dose aspirin) that is not protocol-related
  • Administration of rifampin is prohibited during the study and subjects on concomitant use of rifampin are excluded
  • Has any hepatic disease associated with coagulopathy leading to a clinically relevant bleeding risk
  • Has estimated glomerular filtration rate (eGFR) <30% of normal for age and size
  • Has stage 2 hypertension defined as blood pressure systolic and/or diastolic confirmed >99th percentile plus 5 mmHg
  • Has thrombocytopenia or life expectancy less than three months
  • Has had Fontan procedure with a history of or signs/symptoms suggestive of protein-losing enteropathy
  • Is pregnant or breastfeeding
  • Has a contraindication to the use of heparin and/or vitamin K antagonist (VKA)
  • Has any condition that, as judged by the Investigator, would place the participant at increased risk of harm if he/she participated in the study, including contraindicated medications identified in the protocol

Sites / Locations

  • University of Alabama at Birmingham
  • Cardon Childrens Medical Center
  • Cedars Sinai Medical Center (ECG)
  • University of California-San Francisco Department of Pediatrics - Hematology/Oncology
  • University of Florida College of Medicine
  • Ann & Robert H. Lurie Children's Hospital of Chicago
  • Rush University Medical Center
  • Ochsner Medical Center
  • Novant Health Heart and Vascular institute
  • East Carolina Heart Institute @ ECU
  • Wake Forest University Baptist Medical Center
  • OU Health Sciences Center
  • University of Virginia Health System
  • Seattle Children's Research Institute
  • Kepler Universitätsklinikum Med Campus IV
  • McMaster Children's Hospital
  • CHU Sainte-Justine
  • McGill University Health Centre/Glen Site/Montreal Children's Hospital
  • University Hospital Center Zagreb
  • Zagazig University Hospital
  • Alexandria Clinical Research Center, Faculty of Medicine
  • Kasr Elainy School of Medicine, Abo Elreesh Hospital (Japanese Hospital), Ali Basha Ibrahim ST Faculty of Medicine Cairo University
  • Ain Shams University Hospital
  • Suez Canal University Hospital
  • Hôpital Des Enfants, Bâtiment Modulaire
  • Pediatric and Congenital Cardiology and Pulmonology Department; Arnaud De Villeneuve University Hospital
  • Pediatric Cardiology Department, Hospital Necker Enfants Malades, APHP, Université Paris Descartes
  • Gottsegen Gyorgy Orszagos Kardiologiai Intezet
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
  • Nirmal Hospital Private Limited
  • Institute of Child Health
  • Soroka University Medical Center
  • Hadassah University Hospital - Ein Kerem
  • Sheba Medical Center
  • Children's Heart Centre at the American University of Beirut Medical Center
  • Hotel Dieu de France Hospital
  • Hospital Universitari Vall d'Hebron
  • Erciyes University Medical Faculty, Department of Children Hospital
  • Hacettepe University Medical Faculty
  • Istanbul University Istanbul Medical Faculty
  • Ege University Faculty of Medicine Department of Child Health and Diseases
  • Izmir-Dr. Behçet Uz. Pediatric Diseases and Surgery Training and Research Hospital- Izmir Dr. Behcet Uz Cocuk Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
  • Communal Institution Dnipropetrovsk Regional Pediatric Clinical Hospital of Dnipropetrovsk Regional Council, State Institution Dnipropetrovsk Medical Academy of MoH of Ukraine
  • Communal Healthcare Institution Regional Pediatric Clinical Hospital, Kharkiv National Medical University
  • Vynnitsa Regional Children Clinical Hospital Policlinic Dept
  • Royal Brompton Hospital
  • Glenfield Hospital
  • Ward 2B, Royal Hospital for Children

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Edoxaban

Standard of Care (SOC)

Arm Description

Two out of three participants will be randomized for treatment with edoxaban solution or tablets

One out of three participants will be randomized for treatment with the institution's SOC regimen

Outcomes

Primary Outcome Measures

Number of Participants With Adjudicated Bleeding Events Within the Main Treatment Period
Adjudicated bleeding events included major and clinically-relevant non-major (CRNM) bleeding events per International Society on Thrombosis and Haemostasis (ISTH) definition occurring within the main treatment period. Based on modified ISTH recommendations, major bleeding is defined as a composite (ie, any) of the following: fatal bleeding; and/or symptomatic bleeding in a critical area or organ; and/or bleeding causing a decrease in hemoglobin level of >2 g/dL, or leading to transfusion of the equivalent of ≥2 units of whole blood or red cells. A CRNM bleed is an acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding, or a physician guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. Minor bleeding is any other overt bleeding event that does not meet criteria for either major or CRNM bleeding.

Secondary Outcome Measures

Number of Participants With Symptomatic Thromboembolic Events (TE) in the Systemic Arterial or Venous Pathways Within the Main Treatment Period
Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI).
Number of Participants Who Died as a Result of Thromboembolic Event Within the Main Treatment Period
Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI).
Number of Participants Who Died as a Result of Any Cause (All-Cause Mortality) Within the Main Treatment Period
Death due to any cause (all-cause mortality) was assessed.
Number of Participants With Adjudicated Bleeding Events During the Extension Period
Adjudicated bleeding events included major and clinically-relevant non-major (CRNM) bleeding events per International Society on Thrombosis and Haemostasis (ISTH) definition occurring within the main treatment period. Based on modified ISTH recommendations, major bleeding is defined as a composite (ie, any) of the following: fatal bleeding; and/or symptomatic bleeding in a critical area or organ; and/or bleeding causing a decrease in hemoglobin level of >2 g/dL, or leading to transfusion of the equivalent of ≥2 units of whole blood or red cells. A CRNM bleed is an acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding, or a physician guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. Minor bleeding is any other overt bleeding event that does not meet criteria for either major or CRNM bleeding.
Number of Participants With Symptomatic Thromboembolic Events (TE) in the Systemic Arterial or Venous Pathways During the Extension Period
Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI).
Number of Participants Who Died as a Result of Thromboembolic Event During the Extension Period
Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI).
Number of Participants Who Died as a Result of Any Cause (All-Cause Mortality) During the Extension Period
Death due to any cause (all-cause mortality) was assessed.

Full Information

First Posted
January 4, 2018
Last Updated
July 5, 2022
Sponsor
Daiichi Sankyo, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03395639
Brief Title
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
Official Title
An Open-label, Randomised, Parallel-group, Multicentre, Observational Trial to Evaluate Safety and Efficacy of Edoxaban Tosylate in Children From 38 Weeks Gestational Age to Less Than 18 Years of Age With Cardiac Diseases at Risk of Thromboembolic Events
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
May 15, 2018 (Actual)
Primary Completion Date
December 3, 2021 (Actual)
Study Completion Date
December 3, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Daiichi Sankyo, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A committee will judge the safety and effectiveness of edoxaban and the regular treatment (standard of care). All children in the study will receive free treatment. They will have a 2 in 3 chance to receive edoxaban, and a 1 in 3 chance to receive the standard of care for preventing blood clots. The study will find out if edoxaban is safer and more effective than the standard of care.
Detailed Description
The primary objective is to compare the safety of edoxaban with the standard of care (SOC) in pediatric subjects with cardiac diseases at risk of thromboembolic complications who need primary or secondary anticoagulant prophylaxis with regard to the combination of major and clinically relevant non-major (CRNM) bleeding per International Society on Thrombosis and Haemostasis [ISTH] definition. The key secondary objective is to compare the efficacy of edoxaban against SOC with regard to the development of symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus and myocardial infarction (MI), and asymptomatic intracardiac thrombus identified by cardiac imaging.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Disease
Keywords
Children, Pediatrics, Cardiac disease with potential for thromboembolic complications, Prophylactic treatment, Anticoagulant drugs

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
168 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Edoxaban
Arm Type
Experimental
Arm Description
Two out of three participants will be randomized for treatment with edoxaban solution or tablets
Arm Title
Standard of Care (SOC)
Arm Type
Active Comparator
Arm Description
One out of three participants will be randomized for treatment with the institution's SOC regimen
Intervention Type
Drug
Intervention Name(s)
Edoxaban
Other Intervention Name(s)
Lixiana, Savaysa
Intervention Description
Edoxaban 15 mg or 30 mg tablets for participants 12 to <18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
Intervention Type
Drug
Intervention Name(s)
Standard of Care (SOC)
Other Intervention Name(s)
Warfarin/heparin, Enoxaparin
Intervention Description
Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
Primary Outcome Measure Information:
Title
Number of Participants With Adjudicated Bleeding Events Within the Main Treatment Period
Description
Adjudicated bleeding events included major and clinically-relevant non-major (CRNM) bleeding events per International Society on Thrombosis and Haemostasis (ISTH) definition occurring within the main treatment period. Based on modified ISTH recommendations, major bleeding is defined as a composite (ie, any) of the following: fatal bleeding; and/or symptomatic bleeding in a critical area or organ; and/or bleeding causing a decrease in hemoglobin level of >2 g/dL, or leading to transfusion of the equivalent of ≥2 units of whole blood or red cells. A CRNM bleed is an acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding, or a physician guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. Minor bleeding is any other overt bleeding event that does not meet criteria for either major or CRNM bleeding.
Time Frame
Date of first dose of study drug up to the Month 4 or to the date of last dose of study drug if study treatment was discontinued, whichever was earlier
Secondary Outcome Measure Information:
Title
Number of Participants With Symptomatic Thromboembolic Events (TE) in the Systemic Arterial or Venous Pathways Within the Main Treatment Period
Description
Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI).
Time Frame
Date of first dose of study drug up to the Month 4 or to the date of last dose of study drug if study treatment was discontinued, whichever was earlier
Title
Number of Participants Who Died as a Result of Thromboembolic Event Within the Main Treatment Period
Description
Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI).
Time Frame
Date of first dose of study drug up to the Month 4 or to the date of last dose of study drug if study treatment was discontinued, whichever was earlier
Title
Number of Participants Who Died as a Result of Any Cause (All-Cause Mortality) Within the Main Treatment Period
Description
Death due to any cause (all-cause mortality) was assessed.
Time Frame
Date of first dose of study drug up to the Month 4 or to the date of last dose of study drug if study treatment was discontinued, whichever was earlier
Title
Number of Participants With Adjudicated Bleeding Events During the Extension Period
Description
Adjudicated bleeding events included major and clinically-relevant non-major (CRNM) bleeding events per International Society on Thrombosis and Haemostasis (ISTH) definition occurring within the main treatment period. Based on modified ISTH recommendations, major bleeding is defined as a composite (ie, any) of the following: fatal bleeding; and/or symptomatic bleeding in a critical area or organ; and/or bleeding causing a decrease in hemoglobin level of >2 g/dL, or leading to transfusion of the equivalent of ≥2 units of whole blood or red cells. A CRNM bleed is an acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding, or a physician guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. Minor bleeding is any other overt bleeding event that does not meet criteria for either major or CRNM bleeding.
Time Frame
Month 4 up to Month 13
Title
Number of Participants With Symptomatic Thromboembolic Events (TE) in the Systemic Arterial or Venous Pathways During the Extension Period
Description
Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI).
Time Frame
Month 4 up to Month 13
Title
Number of Participants Who Died as a Result of Thromboembolic Event During the Extension Period
Description
Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI).
Time Frame
Month 4 up to Month 13
Title
Number of Participants Who Died as a Result of Any Cause (All-Cause Mortality) During the Extension Period
Description
Death due to any cause (all-cause mortality) was assessed.
Time Frame
Month 4 up to Month 13

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is a child with cardiac disease who is at risk for thromboembolic complications and requires at least 3 months antithrombotic anticoagulant prophylaxis Either one of the following: a child with cardiac disease who has a history of cardiac shunt occlusion/thrombosis, with shunt still in place (secondary prevention). OR a child with cardiac disease who requires (including those already taking, and those not yet taking) anticoagulation for primary prevention of TE. Cardiac conditions known to significantly increase the risk of thrombosis (hence, indications for primary TE prevention) are defined in Antithrombotic Therapy and Prevention of Thrombosis. Some examples of cardiac conditions at risk of thrombosis are Fontan surgery, heart failure, Kawasaki disease, and Blalock-Taussig and Glenn surgery. Is a male or female child between 1 and <18 years of age (children between 38 weeks gestational age and 1 year of age will be included in the study, however, only after the safety and efficacy data of 50 subjects between 1 and <18 years of age in the edoxaban arm have been evaluated at the end of the 3-month treatment period) Has parent(s)/legal guardian(s) or legally acceptable representative who is informed and provides signed consent for the child, to participate in the study with edoxaban treatment. Pediatric participants with appropriate intellectual maturity will be required to sign an assent form in addition to the signed informed consent from the parent(s)/legal guardian(s) or any legally acceptable representative. If a female subject of childbearing potential, tests negative for pregnancy at Screening and consents to avoid becoming pregnant by using a locally approved contraception method throughout the study Exclusion Criteria: Has evidence of symptomatic venous or arterial thrombosis and/or asymptomatic intracardiac thrombosis confirmed by a transthoracic echocardiogram during study screening period Has mechanical heart valve(s) Has active bleeding or high risk of bleeding contraindicating treatment with anticoagulant Takes antithrombotic therapy (other than low-dose aspirin) that is not protocol-related Administration of rifampin is prohibited during the study and subjects on concomitant use of rifampin are excluded Has any hepatic disease associated with coagulopathy leading to a clinically relevant bleeding risk Has estimated glomerular filtration rate (eGFR) <30% of normal for age and size Has stage 2 hypertension defined as blood pressure systolic and/or diastolic confirmed >99th percentile plus 5 mmHg Has thrombocytopenia or life expectancy less than three months Has had Fontan procedure with a history of or signs/symptoms suggestive of protein-losing enteropathy Is pregnant or breastfeeding Has a contraindication to the use of heparin and/or vitamin K antagonist (VKA) Has any condition that, as judged by the Investigator, would place the participant at increased risk of harm if he/she participated in the study, including contraindicated medications identified in the protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Study Leader
Organizational Affiliation
Daiichi Sankyo, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Facility Name
Cardon Childrens Medical Center
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85202
Country
United States
Facility Name
Cedars Sinai Medical Center (ECG)
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
University of California-San Francisco Department of Pediatrics - Hematology/Oncology
City
San Francisco
State/Province
California
ZIP/Postal Code
94158
Country
United States
Facility Name
University of Florida College of Medicine
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Facility Name
Ann & Robert H. Lurie Children's Hospital of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Ochsner Medical Center
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70121
Country
United States
Facility Name
Novant Health Heart and Vascular institute
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Facility Name
East Carolina Heart Institute @ ECU
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
Facility Name
Wake Forest University Baptist Medical Center
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
OU Health Sciences Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Facility Name
University of Virginia Health System
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Facility Name
Seattle Children's Research Institute
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States
Facility Name
Kepler Universitätsklinikum Med Campus IV
City
Linz
ZIP/Postal Code
4020
Country
Austria
Facility Name
McMaster Children's Hospital
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 3Z5
Country
Canada
Facility Name
CHU Sainte-Justine
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H3T 1C5
Country
Canada
Facility Name
McGill University Health Centre/Glen Site/Montreal Children's Hospital
City
Pierrefonds
State/Province
Quebec
ZIP/Postal Code
H9H 4Y6
Country
Canada
Facility Name
University Hospital Center Zagreb
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Facility Name
Zagazig University Hospital
City
Zagazig
State/Province
Al Sharkeya
ZIP/Postal Code
44519
Country
Egypt
Facility Name
Alexandria Clinical Research Center, Faculty of Medicine
City
Alexandria
ZIP/Postal Code
21131
Country
Egypt
Facility Name
Kasr Elainy School of Medicine, Abo Elreesh Hospital (Japanese Hospital), Ali Basha Ibrahim ST Faculty of Medicine Cairo University
City
Cairo
ZIP/Postal Code
11562
Country
Egypt
Facility Name
Ain Shams University Hospital
City
Cairo
ZIP/Postal Code
11566
Country
Egypt
Facility Name
Suez Canal University Hospital
City
Ismailia
ZIP/Postal Code
41522
Country
Egypt
Facility Name
Hôpital Des Enfants, Bâtiment Modulaire
City
Toulouse cedex 9
State/Province
Haute Garonne
ZIP/Postal Code
31059
Country
France
Facility Name
Pediatric and Congenital Cardiology and Pulmonology Department; Arnaud De Villeneuve University Hospital
City
Montpellier
State/Province
Herault
ZIP/Postal Code
34295
Country
France
Facility Name
Pediatric Cardiology Department, Hospital Necker Enfants Malades, APHP, Université Paris Descartes
City
Paris
State/Province
Paris Cedex 15
ZIP/Postal Code
75015
Country
France
Facility Name
Gottsegen Gyorgy Orszagos Kardiologiai Intezet
City
Budapest
ZIP/Postal Code
1096
Country
Hungary
Facility Name
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
City
Szeged
ZIP/Postal Code
6720
Country
Hungary
Facility Name
Nirmal Hospital Private Limited
City
Sūrat
State/Province
Gujarat
ZIP/Postal Code
395002
Country
India
Facility Name
Institute of Child Health
City
Kolkata
ZIP/Postal Code
700017
Country
India
Facility Name
Soroka University Medical Center
City
Be'er Sheva
ZIP/Postal Code
8410101
Country
Israel
Facility Name
Hadassah University Hospital - Ein Kerem
City
Jerusalem
ZIP/Postal Code
9112001
Country
Israel
Facility Name
Sheba Medical Center
City
Ramat Gan
ZIP/Postal Code
5265601
Country
Israel
Facility Name
Children's Heart Centre at the American University of Beirut Medical Center
City
Beirut
ZIP/Postal Code
11-0236
Country
Lebanon
Facility Name
Hotel Dieu de France Hospital
City
Beirut
ZIP/Postal Code
166830
Country
Lebanon
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Erciyes University Medical Faculty, Department of Children Hospital
City
Edirne
State/Province
Kayseri
ZIP/Postal Code
38039
Country
Turkey
Facility Name
Hacettepe University Medical Faculty
City
Ankara
ZIP/Postal Code
06100
Country
Turkey
Facility Name
Istanbul University Istanbul Medical Faculty
City
Istanbul
ZIP/Postal Code
34093
Country
Turkey
Facility Name
Ege University Faculty of Medicine Department of Child Health and Diseases
City
İzmir
ZIP/Postal Code
35040
Country
Turkey
Facility Name
Izmir-Dr. Behçet Uz. Pediatric Diseases and Surgery Training and Research Hospital- Izmir Dr. Behcet Uz Cocuk Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
City
İzmir
ZIP/Postal Code
35210
Country
Turkey
Facility Name
Communal Institution Dnipropetrovsk Regional Pediatric Clinical Hospital of Dnipropetrovsk Regional Council, State Institution Dnipropetrovsk Medical Academy of MoH of Ukraine
City
Dnipro
ZIP/Postal Code
49100
Country
Ukraine
Facility Name
Communal Healthcare Institution Regional Pediatric Clinical Hospital, Kharkiv National Medical University
City
Kharkiv
ZIP/Postal Code
61093
Country
Ukraine
Facility Name
Vynnitsa Regional Children Clinical Hospital Policlinic Dept
City
Vinnytsia
ZIP/Postal Code
21000
Country
Ukraine
Facility Name
Royal Brompton Hospital
City
London
State/Province
Greater London
ZIP/Postal Code
SW3 6HP
Country
United Kingdom
Facility Name
Glenfield Hospital
City
Leicester
State/Province
Leicestershire
ZIP/Postal Code
LE3 9QP
Country
United Kingdom
Facility Name
Ward 2B, Royal Hospital for Children
City
Glasgow
State/Province
Strathclyde
ZIP/Postal Code
G51 4TF
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing URL
https://vivli.org/ourmember/daiichi-sankyo/

Learn more about this trial

Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

We'll reach out to this number within 24 hrs